Compile Data Set for Download or QSAR
Report error Found 87 Enz. Inhib. hit(s) with all data for entry = 11306
TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM527814((3S,4S)-8-(8-((2- amino-3- chloropyridin-4- yl)thi...)
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM527850((3S,4S)-8-(8-(2,3- dichlorophenyl)-7- methyl- [1,2...)
Affinity DataIC50: 10nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605733(US11673901, Compound 4 | US11673901, Example 4)
Affinity DataIC50: 29nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605786(US11673901, Compound 56)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605785(US11673901, Compound 55)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605784(US11673901, Compound 54)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605791(US11673901, Compound 61)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM527814((3S,4S)-8-(8-((2- amino-3- chloropyridin-4- yl)thi...)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605794(US11673901, Compound 64)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605793(US11673901, Compound 63)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605792(US11673901, Compound 62)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605733(US11673901, Compound 4 | US11673901, Example 4)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605771(US11673901, Compound 41)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605770(US11673901, Compound 40)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605769(US11673901, Compound 39)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605768(US11673901, Compound 38)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605775(US11673901, Compound 45)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605774(US11673901, Compound 44)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605773(US11673901, Compound 43)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605772(US11673901, Compound 42)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605779(US11673901, Compound 49)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605778(US11673901, Compound 48)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605777(US11673901, Compound 47)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605776(US11673901, Compound 46)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605783(US11673901, Compound 53)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605782(US11673901, Compound 52)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605780(US11673901, Compound 50)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605759(US11673901, Compound 29)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605763(US11673901, Compound 33)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605762(US11673901, Compound 32)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605761(US11673901, Compound 31)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605760(US11673901, Compound 30)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605767(US11673901, Compound 37)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605766(US11673901, Compound 36)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605765(US11673901, Compound 35)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605764(US11673901, Compound 34)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605739(US11673901, Compound 9)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM527761((3S,4S)-8-(8-(2,3- dichlorophenyl)-7- methylimidaz...)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM527850((3S,4S)-8-(8-(2,3- dichlorophenyl)-7- methyl- [1,2...)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605743(US11673901, Compound 13)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605742(US11673901, Compound 12)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM527838((3S,4S)-8-(8- ((2,3- dichlorophenyl) thio)imidazo[...)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605740(US11673901, Compound 10)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605747(US11673901, Compound 17)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM527913((3S,4S)-8-(8-((1H- pyrrolo[2,3- b]pyridin-4- yl)th...)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605813(US11673901, Compound 83)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM527819(1-(8-((2,3- dichlorophenyl)thio) imidazo[1,2- c]py...)
Affinity DataIC50: 120nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605787(US11673901, Compound 57)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605755(US11673901, Compound 25)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM605754(US11673901, Compound 24)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

Displayed 1 to 50 (of 87 total ) | Next | Last >>
Jump to: